Stem cell factor receptor/c-Kit: from basic science to clinical implications.

Stem cell factor (SCF) is a dimeric molecule that exerts its biological functions by binding to and activating the receptor tyrosine kinase c-Kit. Activation of c-Kit leads to its autophosphorylation and initiation of signal transduction. Signaling proteins are recruited to activated c-Kit by certain interaction domains (e.g., SH2 and PTB) that specifically bind to phosphorylated tyrosine residues in the intracellular region of c-Kit. Activation of c-Kit signaling has been found to mediate cell survival, migration, and proliferation depending on the cell type. Signaling from c-Kit is crucial for normal hematopoiesis, pigmentation, fertility, gut movement, and some aspects of the nervous system. Deregulated c-Kit kinase activity has been found in a number of pathological conditions, including cancer and allergy. The observation that gain-of-function mutations in c-Kit can promote tumor formation and progression has stimulated the development of therapeutics agents targeting this receptor, e.g., the clinically used inhibitor imatinib mesylate. Also other clinically used multiselective kinase inhibitors, for instance, sorafenib and sunitinib, have c-Kit included in their range of targets. Furthermore, loss-of-function mutations in c-Kit have been observed and shown to give rise to a condition called piebaldism. This review provides a summary of our current knowledge regarding structural and functional aspects of c-Kit signaling both under normal and pathological conditions, as well as advances in the development of low-molecular-weight molecules inhibiting c-Kit function.

[1]  Stephan Rosenkranz,et al.  Phosphatidylinositol 3-Kinase-dependent Membrane Recruitment of Rac-1 and p47phox Is Critical for α-Platelet-derived Growth Factor Receptor-induced Production of Reactive Oxygen Species* , 2008, Journal of Biological Chemistry.

[2]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Heldin,et al.  Activation of the human c‐kit product by ligand‐induced dimerization mediates circular actin reorganization and chemotaxis. , 1991, The EMBO journal.

[4]  B. Calabretta,et al.  Myb and ets proteins are candidate regulators of c-kit expression in human hematopoietic cells. , 1998, Blood.

[5]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[6]  I. Madshus,et al.  Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. , 2004, Experimental cell research.

[7]  B. Neel,et al.  The Scaffolding Adapter Gab2, via Shp-2, Regulates Kit-evoked Mast Cell Proliferation by Activating the Rac/JNK Pathway* , 2006, Journal of Biological Chemistry.

[8]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[9]  L. Looijenga,et al.  Testicular germ-cell tumours in a broader perspective , 2005, Nature Reviews Cancer.

[10]  R. Ueda,et al.  Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. , 1991, Cancer research.

[11]  N. Copeland,et al.  Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles , 1990, Cell.

[12]  S. Lipkowitz,et al.  Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). , 2005, Blood.

[13]  S. Lev,et al.  Steel factor and c-kit protooncogene: genetic lessons in signal transduction. , 1994, Critical reviews in oncogenesis.

[14]  B. Wehrle-Haller The role of Kit-ligand in melanocyte development and epidermal homeostasis. , 2003, Pigment cell research.

[15]  G. Superti-Furga,et al.  Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib , 2008, Leukemia & lymphoma.

[16]  Y. Hayashi,et al.  KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. , 2006, Blood.

[17]  S. Hubbard Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.

[18]  J. Wypych,et al.  Purification and characterization of soluble forms of human and rat stem cell factor recombinantly expressed by Escherichia coli and by Chinese hamster ovary cells. , 1992, Archives of biochemistry and biophysics.

[19]  S. Nishikawa,et al.  Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse. , 1991, Nucleic acids research.

[20]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[21]  L. Thomas,et al.  Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. , 2010, The Journal of investigative dermatology.

[22]  C. Heldin,et al.  Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C. , 1994, The Journal of biological chemistry.

[23]  M. Odenthal,et al.  Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors. , 2011, International journal of oncology.

[24]  C. Blobel,et al.  Catalytic Properties of ADAM19* , 2003, Journal of Biological Chemistry.

[25]  A. Newton,et al.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. , 2007, Molecular cell.

[26]  S. Nishikawa,et al.  Expression and function of c-kit in hemopoietic progenitor cells , 1991, The Journal of experimental medicine.

[27]  A. Ullrich,et al.  Progression of human cutaneous melanoma is associated with loss of expression of c‐kit proto‐oncogene receptor , 1992, International journal of cancer.

[28]  Asim Khwaja,et al.  The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases* , 2003, The Journal of Biological Chemistry.

[29]  F. Ruddle,et al.  Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. , 1988, The EMBO journal.

[30]  Bengt Phung,et al.  C-KIT Signaling Depends on Microphthalmia-Associated Transcription Factor for Effects on Cell Proliferation , 2011, PloS one.

[31]  C. Heldin,et al.  Involvement of phosphatidylinositol 3'-kinase in stem-cell-factor-induced phospholipase D activation and arachidonic acid release. , 1997, European journal of biochemistry.

[32]  C. Sette,et al.  Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. , 2004, The American journal of pathology.

[33]  C. Sette,et al.  Expression of a truncated form of KIT tyrosine kinase in human spermatozoa correlates with sperm DNA integrity. , 2010, Human reproduction.

[34]  P. Stein,et al.  Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor. , 2006, Cellular signalling.

[35]  T. Kamijo,et al.  Analysis of synergism between stem cell factor and granulocyte-macrophage colony-stimulating factor on human megakaryoblastic cells: an increase in tyrosine phosphorylation of 145 kDa subunit of c-kit in two-factor combination. , 1997, Leukemia research.

[36]  J. Venables,et al.  tr-kit promotes the formation of a multimolecular complex composed by Fyn, PLCγ1 and Sam68 , 2003, Oncogene.

[37]  Li-li Wang,et al.  MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. , 2011, Leukemia research.

[38]  Avijit Chakrabartty,et al.  Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region , 2003, Molecular and Cellular Biology.

[39]  P. Besmer,et al.  Kit signaling through PI 3‐kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation , 1998, The EMBO journal.

[40]  V. Broudy,et al.  Stem cell factor and hematopoiesis. , 1997, Blood.

[41]  D. Sabatini,et al.  mTOR signaling at a glance , 2009, Journal of Cell Science.

[42]  A. Gotoh,et al.  Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells. , 1994, Blood.

[43]  A. Strife,et al.  c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells. , 1996, Leukemia.

[44]  L. Rönnstrand,et al.  The D816V Mutation of c-Kit Circumvents a Requirement for Src Family Kinases in c-Kit Signal Transduction* , 2009, Journal of Biological Chemistry.

[45]  L. Rönnstrand,et al.  Grb2 mediates negative regulation of stem cell factor receptor/c-Kit signaling by recruitment of Cbl. , 2007, Experimental cell research.

[46]  M. Gerritsen,et al.  Targeting Protein Kinases for Cancer Therapy , 2010 .

[47]  E Leonard,et al.  Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. , 2001, Blood.

[48]  J. Soboloff,et al.  Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation , 2003, Cellular and Molecular Life Sciences CMLS.

[49]  Youmei Feng,et al.  Stem cell factor/c-kit signaling mediated cardiac stem cell migration via activation of p38 MAPK , 2008, Basic Research in Cardiology.

[50]  B. Vanhaesebroeck,et al.  Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma , 2008, Nature Medicine.

[51]  B. Foster,et al.  Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). , 1999, Blood.

[52]  D. Dembélé,et al.  Genome‐wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene , 2010, Pigment cell & melanoma research.

[53]  J. Jaffrezou,et al.  Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: implication in stem cell factor radioprotective effect. , 2002, Blood.

[54]  A. Craig,et al.  Fps/Fes protein-tyrosine kinase regulates mast cell adhesion and migration downstream of Kit and beta1 integrin receptors. , 2010, Cellular signalling.

[55]  K. Takatsu,et al.  Roles of a conserved family of adaptor proteins, Lnk, SH2-B, and APS, for mast cell development, growth, and functions: APS-deficiency causes augmented degranulation and reduced actin assembly. , 2004, Biochemical and biophysical research communications.

[56]  H. Mano,et al.  Stem cell factor induces phosphatidylinositol 3'-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells. , 2000, Blood.

[57]  D. Brann,et al.  Neuroprotection by stem cell factor in rat cortical neurons involves AKT and NFκB , 2005, Journal of neurochemistry.

[58]  G. Nilsson,et al.  Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. , 2005, Blood.

[59]  S Torihashi,et al.  Mutation of the proto‐oncogene c‐kit blocks development of interstitial cells and electrical rhythmicity in murine intestine. , 1994, The Journal of physiology.

[60]  T. Hirano,et al.  Requirement of Gab2 for mast cell development and KitL/c-Kit signaling. , 2002, Blood.

[61]  J. Schlessinger Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[62]  Alastair,et al.  Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. , 1991, The EMBO journal.

[63]  S. Mane,et al.  Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2. , 2002, Blood.

[64]  Lixin Sun,et al.  Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. , 2004, The Journal of clinical investigation.

[65]  David A. Williams,et al.  Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential. , 2000, Blood.

[66]  N. Copeland,et al.  Multiple pathways for Steel regulation suggested by genomic and sequence analysis of the murine Steel gene. , 1996, Genetics.

[67]  A. Yoshimura,et al.  The adapter protein APS associates with the multifunctional docking sites Tyr-568 and Tyr-936 in c-Kit. , 2003, The Biochemical journal.

[68]  U. Hellman,et al.  Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c-Crk. , 2003, Experimental cell research.

[69]  T. Hunter,et al.  The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136 , 1998, Current Biology.

[70]  A. Joachimiak,et al.  Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[71]  W. Pavan,et al.  Melanocyte development in vivo and in neural crest cell cultures: crucial dependence on the Mitf basic-helix-loop-helix-zipper transcription factor. , 1997, Development.

[72]  S. Hirota,et al.  Impairment of spatial learning and hippocampal synaptic potentiation in c-kit mutant rats. , 2000, Learning & memory.

[73]  I. Matsumura,et al.  Critical roles of c-Kit tyrosine residues 567 and 719 in stem cell factor-induced chemotaxis: contribution of src family kinase and PI3-kinase on calcium mobilization and cell migration. , 2002, Blood.

[74]  P. Dubreuil,et al.  The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. , 2007, Blood.

[75]  D. Housman,et al.  The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene , 1988, Cell.

[76]  P. Pandolfi,et al.  62 dok , a Negative Regulator of Ras and Mitogen-activated Protein Kinase ( MAPK ) Activity , Opposes Leukemogenesis by p 210 bcr-abl , 2001 .

[77]  I. Lax,et al.  Kit Receptor Dimerization Is Driven by Bivalent Binding of Stem Cell Factor* , 1997, The Journal of Biological Chemistry.

[78]  P. Lavori,et al.  Direct interaction between Kit and the interleukin-7 receptor. , 2007, Blood.

[79]  P. Rossi,et al.  A novel c-kit transcript, potentially encoding a truncated receptor, originates within a kit gene intron in mouse spermatids. , 1992, Developmental biology.

[80]  M. Dym,et al.  Stem Cell Factor/c-kit Up-regulates Cyclin D3 and Promotes Cell Cycle Progression via the Phosphoinositide 3-Kinase/p70 S6 Kinase Pathway in Spermatogonia* , 2000, The Journal of Biological Chemistry.

[81]  Philip,et al.  Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. , 1993, Blood.

[82]  A. N. Meyer,et al.  Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. , 2000, Molecular biology of the cell.

[83]  P. Pandolfi,et al.  P62dok, a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210bcr-abl , 2001, The Journal of experimental medicine.

[84]  T. Hunter,et al.  Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility , 2000, Nature Genetics.

[85]  C. Sette,et al.  Molecular mechanisms utilized by alternative c‐kit gene products in the control of spermatogonial proliferation and sperm‐mediated egg activation , 2003, Andrologia.

[86]  J. Litz,et al.  Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. , 1998, Cancer research.

[87]  H. Kitayama,et al.  Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells. , 1993, Leukemia & lymphoma.

[88]  R. Ueda,et al.  Ectopic expression of c‐kit in small‐cell lung cancer , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[89]  R. Spritz,et al.  Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[90]  L. Landi,et al.  Contribution of reactive oxygen species to the regulation of Glut1 in two hemopoietic cell lines differing in cytokine sensitivity. , 2004, Free radical biology & medicine.

[91]  G. Nilsson,et al.  Stem cell factor-induced migration of mast cells requires p38 mitogen-activated protein kinase activity. , 2001, Experimental cell research.

[92]  C. Peschel,et al.  Role for the Adaptor Protein Grb10 in the Activation of Akt , 2002, Molecular and Cellular Biology.

[93]  G. Krystal,et al.  Selective Sp1 binding is critical for maximal activity of the human c-kit promoter. , 1998, Blood.

[94]  N. Lassam,et al.  Loss of c-kit expression in cultured melanoma cells. , 1992, Oncogene.

[95]  T. Ouchi,et al.  Downstream of Crk adaptor signaling pathway: activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[96]  B. Brockway,et al.  c-Kit is essential for alveolar maintenance and protection from emphysema-like disease in mice. , 2011, American journal of respiratory and critical care medicine.

[97]  Joo-Heon Yoon,et al.  Chrysin inhibited stem cell factor (SCF)/c-Kit complex-induced cell proliferation in human myeloid leukemia cells. , 2007, Biochemical pharmacology.

[98]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[99]  D. Frank,et al.  SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways. , 2000, Blood.

[100]  M. Tainsky,et al.  Loss of AP‐2 results in downregulation of c‐KIT and enhancement of melanoma tumorigenicity and metastasis , 1998, The EMBO journal.

[101]  G. Superti-Furga,et al.  Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells , 2009, Leukemia.

[102]  I. Jackson,et al.  Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo. , 1997, Developmental biology.

[103]  M. Minden,et al.  Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia. , 1994, Blood.

[104]  D. Margulies,et al.  Surface Binding Inhibitors of the SCF–KIT Protein–Protein Interaction , 2009, Chembiochem : a European journal of chemical biology.

[105]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[106]  M. Shibuya,et al.  Characterization of the Promoter Region of the Human c‐kit Proto‐oncogene , 1993, Japanese journal of cancer research : Gann.

[107]  L. Rönnstrand,et al.  Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism , 2006, British Journal of Cancer.

[108]  E Soffer,et al.  Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation , 2002, Gut.

[109]  M. Brüss,et al.  Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder , 2007, Scandinavian journal of gastroenterology.

[110]  David Perahia,et al.  Mutation D816V Alters the Internal Structure and Dynamics of c-KIT Receptor Cytoplasmic Region: Implications for Dimerization and Activation Mechanisms , 2011, PLoS Comput. Biol..

[111]  Frédéric Subra,et al.  The Aberrant Localization of Oncogenic Kit Tyrosine Kinase Receptor Mutants Is Reversed on Specific Inhibitory Treatment , 2009, Molecular Cancer Research.

[112]  Michael H. Tomasson,et al.  Neoplasia Driven by Mutant c-KIT Is Mediated by Intracellular, Not Plasma Membrane, Receptor Signaling , 2006, Molecular and Cellular Biology.

[113]  B. Hemmings,et al.  A Human Protein Kinase Bγ with Regulatory Phosphorylation Sites in the Activation Loop and in the C-terminal Hydrophobic Domain* , 1999, The Journal of Biological Chemistry.

[114]  H. Serve,et al.  Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. , 1994, The Journal of biological chemistry.

[115]  C. Croce,et al.  Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-q24. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[116]  S. Lev,et al.  Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[117]  L. Ashman,et al.  Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. , 2002, Molecular cancer therapeutics.

[118]  H. Kitayama,et al.  Changes in phenotype and proliferative potential of human acute myeloblastic leukemia cells in culture with stem cell factor. , 1993, Experimental hematology.

[119]  Y. Sakuma,et al.  Alterations of the c‐kit gene in testicular germ cell tumors , 2003, Cancer science.

[120]  Y. Kitamura,et al.  Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. , 2003, Blood.

[121]  H. Beug,et al.  Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors , 2004, The Journal of experimental medicine.

[122]  L. Cantley,et al.  Identification of two SH3-binding motifs in the regulatory subunit of phosphatidylinositol 3-kinase. , 1994, The Journal of biological chemistry.

[123]  N. Copeland,et al.  Embryonic RNA expression patterns of the c‐kit receptor and its cognate ligand suggest multiple functional roles in mouse development. , 1991, The EMBO journal.

[124]  E. Heiss,et al.  Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. , 2006, The Biochemical journal.

[125]  Shan Zeng,et al.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. , 2002, Blood.

[126]  R. Perlmutter,et al.  Control of B cell production by the adaptor protein lnk. Definition Of a conserved family of signal-modulating proteins. , 2000, Immunity.

[127]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[128]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[129]  Shinichi Watanabe,et al.  UVB irradiation increases the release of SCF from human epidermal cells. , 2005, The Journal of investigative dermatology.

[130]  P. Blume-Jensen,et al.  Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction , 1999, Oncogene.

[131]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[132]  S. Rafii,et al.  Role of c-kit/Kit ligand signaling in regulating vasculogenesis , 2003, Thrombosis and Haemostasis.

[133]  L. Rönnstrand,et al.  Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c‐Kit stimulation , 2007, British journal of haematology.

[134]  T. Arakawa,et al.  Glycosylated and unglycosylated recombinant-derived human stem cell factors are dimeric and have extensive regular secondary structure. , 1991, The Journal of biological chemistry.

[135]  K. Loveland,et al.  Stem cell factor and c-kit in the mammalian testis: lessons originating from Mother Nature's gene knockouts. , 1997, The Journal of endocrinology.

[136]  Kohjiro Ueki,et al.  Molecular Balance between the Regulatory and Catalytic Subunits of Phosphoinositide 3-Kinase Regulates Cell Signaling and Survival , 2002, Molecular and Cellular Biology.

[137]  M. Vihinen,et al.  Phylogeny of Tec family kinases identification of a premetazoan origin of Btk, Bmx, Itk, Tec, Txk, and the Btk regulator SH3BP5. , 2008, Advances in genetics.

[138]  M. Hirano,et al.  The interaction of small domains between the subunits of phosphatidylinositol 3-kinase determines enzyme activity. , 1994, Molecular and cellular biology.

[139]  L. Rönnstrand,et al.  Stem cell factor induces HIF-1alpha at normoxia in hematopoietic cells. , 2008, Biochemical and biophysical research communications.

[140]  Joanne Oates,et al.  Strong oligomerization behavior of PDGFbeta receptor transmembrane domain and its regulation by the juxtamembrane regions. , 2010, Biochimica et biophysica acta.

[141]  B. Liu,et al.  Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). , 2008, Carcinogenesis.

[142]  T. Pawson,et al.  Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[143]  C. Sette,et al.  Parthenogenetic activation of mouse eggs by microinjection of a truncated c-kit tyrosine kinase present in spermatozoa. , 1997, Development.

[144]  R. Salgia,et al.  Hematopoietic growth factors signal through the formation of reactive oxygen species. , 1999, Blood.

[145]  F. Lordick,et al.  The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107 , 2005, Leukemia.

[146]  R. Halaban,et al.  Chymase cleavage of stem cell factor yields a bioactive, soluble product. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[147]  S. Woodman,et al.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. , 2010, Biochemical pharmacology.

[148]  C. Deberry,et al.  Lyn Associates with the Juxtamembrane Region of c-Kit and Is Activated by Stem Cell Factor in Hematopoietic Cell Lines and Normal Progenitor Cells* , 1997, The Journal of Biological Chemistry.

[149]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[150]  D. Linnekin,et al.  Lyn contributes to regulation of multiple Kit-dependent signaling pathways in murine bone marrow mast cells. , 2005, Cellular signalling.

[151]  D. Metcalfe,et al.  Human Mast Cell Apoptosis Is Regulated Through Bcl-2 and Bcl-XL , 2001, Journal of Clinical Immunology.

[152]  西尾 充史 Stem Cell Factor Prevents Fas-Mediated Apoptosis of Human Erythroid Precursor Cells with Src-Family Kinase Dependency , 2001 .

[153]  M. Giorgio,et al.  A cell- and developmental stage-specific promoter drives the expression of a truncated c-kit protein during mouse spermatid elongation. , 1996, Development.

[154]  C. Heldin,et al.  Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. , 1993, The EMBO journal.

[155]  S. Krantz,et al.  Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. , 1998, Blood.

[156]  F. Galibert,et al.  Localization of the human c-kit protooncogene on the q11–q12 region of chromosome 4 , 1988, Human Genetics.

[157]  Mi‐Sun Kim,et al.  Activation and Function of the mTORC1 Pathway in Mast Cells1 , 2008, The Journal of Immunology.

[158]  G. Nilsson,et al.  The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis. , 2001, Blood.

[159]  Joseph Schlessinger,et al.  Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor , 2007, Cell.

[160]  D. Jain,et al.  Role of Interstitial Cells of Cajal in Motility Disorders of the Bowel , 2003, American Journal of Gastroenterology.

[161]  Sheila M. Thomas,et al.  Specific and redundant roles of Src and Fyn in organizing the cytoskeleton , 1995, Nature.

[162]  Pier Paolo Di Fiore,et al.  Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation , 2003, Nature Cell Biology.

[163]  D. Sacks,et al.  Protein scaffolds in MAP kinase signalling. , 2009, Cellular signalling.

[164]  P. Lincoln,et al.  Inhibition of stem cell factor reduces pulmonary cytokine levels during allergic airway responses , 2004, Clinical and experimental immunology.

[165]  J. Matsui,et al.  Stem Cell Factor/c-kit Signaling Promotes the Survival, Migration, and Capillary Tube Formation of Human Umbilical Vein Endothelial Cells* , 2004, Journal of Biological Chemistry.

[166]  S. Korsmeyer,et al.  Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.

[167]  K. Zsebo,et al.  Primary structure and functional expression of rat and human stem cell factor DNAs , 1990, Cell.

[168]  L. Ashman,et al.  Internalization of Kit together with stem cell factor on human fetal liver-derived mast cells: new protein and RNA synthesis are required for reappearance of Kit. , 1996, Journal of immunology.

[169]  M. Minden,et al.  Alternate splicing creates two forms of the human kit protein. , 1994, Leukemia & lymphoma.

[170]  S. Nishikawa,et al.  Requirement of c-kit for development of intestinal pacemaker system. , 1992, Development.

[171]  S. Bhasin,et al.  Human stem cell factor promoter deoxyribonucleic acid sequence and regulation by cyclic 3',5'-adenosine monophosphate in a Sertoli cell line. , 1996, Endocrinology.

[172]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[173]  J. Blay,et al.  KIT Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal Tumors , 2008, Clinical Cancer Research.

[174]  M. Engström,et al.  Inactivation of the forkhead transcription factor FoxO3 is essential for PKB-mediated survival of hematopoietic progenitor cells by kit ligand. , 2003, Experimental hematology.

[175]  S. Corey,et al.  Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. , 1999, Blood.

[176]  P. Sathyanarayana,et al.  A KIT juxtamembrane PY567 -directed pathway provides nonredundant signals for erythroid progenitor cell development and stress erythropoiesis. , 2009, Experimental hematology.

[177]  Chuanfeng Wu,et al.  C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice , 2011, Proceedings of the National Academy of Sciences.

[178]  E. Russell Hereditary anemias of the mouse: a review for geneticists. , 1979, Advances in genetics.

[179]  S. Corvera,et al.  Specific Association of the β Isoform of the p85 Subunit of Phosphatidylinositol-3 Kinase with the Proto-oncogene c-cbl(*) , 1995, The Journal of Biological Chemistry.

[180]  H. Kitayama,et al.  Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. , 1991, Blood.

[181]  A. Arcaro,et al.  Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? , 2007, Cancer treatment reviews.

[182]  S. Fazel,et al.  Activation of c‐kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[183]  B. Neel,et al.  Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. , 2004, Molecular cell.

[184]  J. Guan,et al.  The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions , 2001, Oncogene.

[185]  C. Hogaboam,et al.  Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma , 2006, Laboratory Investigation.

[186]  A. Ray,et al.  Signaling of c‐kit in dendritic cells influences adaptive immunity , 2010, Annals of the New York Academy of Sciences.

[187]  C. Kress,et al.  Spatial and temporal patterns of c-kit-expressing cells in WlacZ/+ and WlacZ/WlacZ mouse embryos. , 1996, Development.

[188]  M. Gordon Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study , 2008 .

[189]  A. Gotoh,et al.  Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells , 1994 .

[190]  U. Khanzada,et al.  Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling. , 2007, Cellular signalling.

[191]  C. Sette,et al.  Tr‐kit‐induced resumption of the cell cycle in mouse eggs requires activation of a Src‐like kinase , 2002, The EMBO journal.

[192]  V. Chapman,et al.  The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus , 1988, Nature.

[193]  K. Guan,et al.  Regulation of Raf through Phosphorylation and N Terminus-C Terminus Interaction* , 2003, Journal of Biological Chemistry.

[194]  M. Stratton,et al.  Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: Report of 220 tumors and review of literature , 2008, Genes, chromosomes & cancer.

[195]  S. Knapp,et al.  Structural Basis for c-KIT Inhibition by the Suppressor of Cytokine Signaling 6 (SOCS6) Ubiquitin Ligase* , 2010, The Journal of Biological Chemistry.

[196]  L. Rönnstrand,et al.  Gab2 Is Involved in Differential Phosphoinositide 3-Kinase Signaling by Two Splice Forms of c-Kit* , 2008, Journal of Biological Chemistry.

[197]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[198]  D. Metcalfe Mast cells and mastocytosis. , 2008, Blood.

[199]  R. Y. Chow,et al.  A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain. , 1999, The Biochemical journal.

[200]  R. Salgia,et al.  Steel Factor Induces Tyrosine Phosphorylation of CRKL and Binding of CRKL to a Complex Containing c-Kit, Phosphatidylinositol 3-Kinase, and p120CBL* , 1997, The Journal of Biological Chemistry.

[201]  T. Dexter,et al.  Investigation of the molecular mechanisms underlying growth factor synergy: the role of ERK 2 activation in synergy. , 1998, Growth factors.

[202]  A. Mui,et al.  Steel factor stimulates the serine/threonine phosphorylation of the interleukin-3 receptor. , 1994, The Journal of biological chemistry.

[203]  S. Cook,et al.  Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim* , 2003, Journal of Biological Chemistry.

[204]  C. Abboud,et al.  Stem cell factor regulates human melanocyte-matrix interactions. , 1994, Pigment cell research.

[205]  Angela Greco,et al.  A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. , 2004, Gastroenterology.

[206]  Yan Zhang,et al.  Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance. , 2010, Journal of biochemistry.

[207]  Wei Zhang,et al.  A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors , 2004, Cancer Research.

[208]  H. Kitayama,et al.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.

[209]  Alessandro Beghini,et al.  KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. , 2004, Haematologica.

[210]  B. Falini,et al.  Molecular detection of GNNK− and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia , 2007, Leukemia.

[211]  P. Dent,et al.  Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[212]  Miki Ebisuya,et al.  Continuous ERK Activation Downregulates Antiproliferative Genes throughout G1 Phase to Allow Cell-Cycle Progression , 2006, Current Biology.

[213]  M. Mann,et al.  Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. , 2009, Molecular cell.

[214]  John Malysz,et al.  W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity , 1995, Nature.

[215]  S. Braun,et al.  Transcriptional and ERK1/2-dependent synergistic upregulation of p21(cip1/waf1) associated with steel factor synergy in MO7e. , 2001, Biochemical and biophysical research communications.

[216]  D. Metcalfe,et al.  Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. , 2001, Blood.

[217]  S. Jiang,et al.  Direct Association of Csk Homologous Kinase (CHK) with the Diphosphorylated Site Tyr568/570 of the Activated c-KIT in Megakaryocytes* , 1997, The Journal of Biological Chemistry.

[218]  J. Chernoff,et al.  Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. , 2008, Blood.

[219]  K. Wilson,et al.  Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[220]  H. Serve,et al.  Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3'-kinase, and protein kinase C. , 1994, The Journal of biological chemistry.

[221]  K. Manova,et al.  Point mutation in Kit receptor tyrosine kinase reveals essential roles for Kit signaling in spermatogenesis and oogenesis without affecting other Kit responses , 2000, The EMBO journal.

[222]  N. Lukacs,et al.  Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. , 2005, American journal of respiratory and critical care medicine.

[223]  R. Palmer,et al.  Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines. , 2004, Blood.

[224]  G. Bokoch Biology of the p21-activated kinases. , 2003, Annual review of biochemistry.

[225]  A Magnan,et al.  Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics , 2009, Allergy.

[226]  A. Burns,et al.  Impaired development of interstitial cells and intestinal electrical rhythmicity in steel mutants. , 1995, The American journal of physiology.

[227]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[228]  J. Duyster,et al.  E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. , 2009, Blood.

[229]  C. Kahn,et al.  Increased P85α Is a Potent Negative Regulator of Skeletal Muscle Insulin Signaling and Induces in Vivo Insulin Resistance Associated with Growth Hormone Excess* , 2005, Journal of Biological Chemistry.

[230]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[231]  M. Barbacid,et al.  Steel factor stimulates the tyrosine phosphorylation of the proto-oncogene product, p95vav, in human hemopoietic cells. , 1992, The Journal of biological chemistry.

[232]  M. Shibuya,et al.  A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. , 1992, Biochemical and biophysical research communications.

[233]  C. Damsky,et al.  FAK integrates growth-factor and integrin signals to promote cell migration , 2000, Nature Cell Biology.

[234]  P. Valent,et al.  Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives , 2010, Expert review of hematology.

[235]  K. Jin,et al.  Stem cell factor stimulates neurogenesis in vitro and in vivo. , 2002, The Journal of clinical investigation.

[236]  I. Craig,et al.  Report of the committee on the genetic constitution of chromosomes 12 and 13. , 1989, Cytogenetics and cell genetics.

[237]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[238]  H. Fuchs,et al.  Genomewide linkage analysis identifies novel genetic Loci for lung function in mice. , 2005, American journal of respiratory and critical care medicine.

[239]  T. Kondo,et al.  Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice. , 1996, Blood.

[240]  L. Scott,et al.  Human Mast Cells Arise From a Progenitor Cell Population That Is CD 34 1 , c-kit , 1999 .

[241]  Giovanni Camussi,et al.  C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium. , 2007, Blood.

[242]  L. Rönnstrand,et al.  Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. , 1999, The Biochemical journal.

[243]  C. Pallen,et al.  Protein-tyrosine Phosphatase α Regulates Stem Cell Factor-dependent c-Kit Activation and Migration of Mast Cells* , 2008, Journal of Biological Chemistry.

[244]  M. Neurath,et al.  Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. , 2001, The Journal of allergy and clinical immunology.

[245]  J. Glenney,et al.  Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton , 1989, The Journal of cell biology.

[246]  M. Ballmaier,et al.  Downregulation of c-kit expression in human endothelial cells by inflammatory stimuli. , 1997, Blood.

[247]  T. Ishizuka,et al.  MEKK2 gene disruption causes loss of cytokine production in response to IgE and c‐Kit ligand stimulation of ES cell‐derived mast cells , 2000, The EMBO journal.

[248]  M. Resh,et al.  Phosphatidylinositol 3-Kinase and Src Family Kinases Are Required for Phosphorylation and Membrane Recruitment of Dok-1 in c-Kit Signaling* , 2002, The Journal of Biological Chemistry.

[249]  G. Marcucci Core binding factor acute myeloid leukemia. , 2006, Clinical advances in hematology & oncology : H&O.

[250]  E. Nishida,et al.  Shp2, an SH2-containing Protein-tyrosine Phosphatase, Positively Regulates Receptor Tyrosine Kinase Signaling by Dephosphorylating and Inactivating the Inhibitor Sprouty* , 2004, Journal of Biological Chemistry.

[251]  T Pawson,et al.  Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[252]  R. Graham,et al.  c-kit Is Required for Cardiomyocyte Terminal Differentiation , 2008, Circulation research.

[253]  G. Laurent,et al.  Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cγ , 2001, Oncogene.

[254]  C. Miething,et al.  Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain , 2002, Oncogene.

[255]  Y. Nozawa,et al.  SCF/c-kit receptor-mediated arachidonic acid liberation in rat mast cells. Involvement of PLD activation associated tyrosine phosphorylation. , 1993, Biochemical and biophysical research communications.

[256]  T. Pietsch Paracrine and autocrine growth mechanisms of human stem cell factor (c-kit ligand) in myeloid leukemia. , 1993, Nouvelle revue francaise d'hematologie.

[257]  Duc Hung Le,et al.  SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain , 1998, Molecular and Cellular Biology.

[258]  S. Véronneau,et al.  Signal-Regulated Kinase Activation Mobilization and Extracellular Platelet-Activating Factor-Mediated Calcium Caveolae Facilitate but Are Not Essential for , 2009 .

[259]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[260]  C. Croce,et al.  MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[261]  P. Dubreuil,et al.  The E3 ubiquitin ligase HOIL‐1 induces the polyubiquitination and degradation of SOCS6 associated proteins , 2006, FEBS letters.

[262]  Narasimhan P. Agaram,et al.  L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition , 2007, International journal of cancer.

[263]  M. Karin,et al.  Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.

[264]  E. Chien,et al.  Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation* , 2003, Journal of Biological Chemistry.

[265]  K. Manova,et al.  Critical Role for Kit-mediated Src Kinase But Not PI 3-Kinase Signaling in Pro T and Pro B Cell Development , 2004, The Journal of experimental medicine.

[266]  E. Price,et al.  MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes , 1998, Nature.

[267]  M. Gassmann,et al.  Rescue of lethal c-KitW/W mice by erythropoietin. , 2004, Blood.

[268]  N. Varin‐Blank,et al.  Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. , 2008, Blood.

[269]  R. Kapur,et al.  A Novel Mechanism of Cooperation between c-Kit and Erythropoietin Receptor , 2001, The Journal of Biological Chemistry.

[270]  G. Pagès,et al.  Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function , 2003, Oncogene.

[271]  Thomas Kamradt,et al.  The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. , 2010, Blood.

[272]  Satoshi Takaki,et al.  Enhanced Hematopoiesis by Hematopoietic Progenitor Cells Lacking Intracellular Adaptor Protein, Lnk , 2002, The Journal of experimental medicine.

[273]  L. Ashman,et al.  Src Family Kinases Are Involved in the Differential Signaling from Two Splice Forms of c-Kit* , 2003, The Journal of Biological Chemistry.

[274]  S. Galli,et al.  Cloning and functional analysis of the mouse c-kit promoter. , 1993, Biochemical and biophysical research communications.

[275]  Y. Yarden,et al.  Developmental expression of c-kit, a proto-oncogene encoded by the W locus. , 1990, Development.

[276]  Z. Abdel‐Malek,et al.  Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. , 2011, Molecular endocrinology.

[277]  C. Fletcher,et al.  The Role of MITF Phosphorylation Sites During Coat Color and Eye Development in Mice Analyzed by Bacterial Artificial Chromosome Transgene Rescue , 2009, Genetics.

[278]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[279]  V. Broudy,et al.  Analysis of c-kit receptor dimerization by fluorescence resonance energy transfer. , 1998, Blood.

[280]  C. March,et al.  Identification of a ligand for the c-kit proto-oncogene , 1990, Cell.

[281]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[282]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[283]  L. Rönnstrand,et al.  The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. , 2009, Cellular signalling.

[284]  O. Igoucheva,et al.  MicroRNA-dependent regulation of cKit in cutaneous melanoma. , 2009, Biochemical and biophysical research communications.

[285]  A. Hachiya,et al.  The paracrine role of stem cell factor/c-kit signaling in the activation of human melanocytes in ultraviolet-B-induced pigmentation. , 2001, The Journal of investigative dermatology.

[286]  D. Metcalfe,et al.  Mast cells. , 1997, Physiological reviews.

[287]  S. Nishikawa,et al.  Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule. , 1991, Blood.

[288]  H. Lodish,et al.  Interaction of the erythropoietin and stem-cell-factor receptors , 1995, Nature.

[289]  Elizabeth Yang,et al.  Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.

[290]  Timothy J. Yeatman,et al.  Activating SRC mutation in a subset of advanced human colon cancers , 1999, Nature Genetics.

[291]  D. van der Kooy,et al.  Steel mutant mice are deficient in hippocampal learning but not long-term potentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[292]  D. Wojchowski,et al.  KIT associated intracellular tyrosines play an essential role in EpoR co-signaling. , 2008, Cellular signalling.

[293]  H. Wiley,et al.  Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. , 2001, Molecular biology of the cell.

[294]  R. Chan,et al.  Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT. , 2008, Experimental hematology.

[295]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[296]  Jun Zou,et al.  Catalytic Activity of Human ADAM33* , 2004, Journal of Biological Chemistry.

[297]  Ji-Young Kim,et al.  Stem cell factor induces ERM proteins phosphorylation through PI3K activation to mediate melanocyte proliferation and migration , 2009, Pigment cell & melanoma research.

[298]  D. Linnekin,et al.  Lyn is activated during late G1 of stem-cell-factor-induced cell cycle progression in haemopoietic cells. , 1999, The Biochemical journal.

[299]  J. Lennartsson,et al.  Synergistic Growth of Stem Cell Factor and Granulocyte Macrophage Colony-stimulating Factor Involves Kinase-dependent and -independent Contributions from c-Kit* , 2004, Journal of Biological Chemistry.

[300]  R. Chan,et al.  Kinase suppressor of Ras (KSR1) modulates multiple kit-ligand-dependent mast cell functions. , 2011, Experimental hematology.

[301]  J. Litz,et al.  Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1α activity and vascular endothelial growth factor expression in small cell lung cancer cells , 2006, Molecular Cancer Therapeutics.

[302]  S. Verma,et al.  Stem Cell Factor Attenuates Vascular Smooth Muscle Apoptosis and Increases Intimal Hyperplasia After Vascular Injury , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[303]  L. Ashman,et al.  Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts , 1999, Oncogene.

[304]  B. Druker,et al.  Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[305]  T Takahashi,et al.  Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. , 1991, Oncogene.

[306]  Michael A McDevitt,et al.  KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. , 2011, Blood.

[307]  I. Dikic,et al.  Compartmentalization of growth factor receptor signalling. , 2005, Current opinion in cell biology.

[308]  J. Hartley,et al.  Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[309]  B. Hogan,et al.  Embryonic expression of a haematopoietic growth factor encoded by the SI locus and the ligand for c-kit , 1990, Nature.

[310]  R. Reeves,et al.  Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells , 2004, Oncogene.

[311]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[312]  C. Wernstedt,et al.  Identification of the Major Phosphorylation Sites for Protein Kinase C in Kit/Stem Cell Factor Receptor in Vitro and in Intact Cells (*) , 1995, The Journal of Biological Chemistry.

[313]  D. McConkey,et al.  Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. , 1996, Oncogene.

[314]  Li-quan Hong,et al.  c-Kit-Mediated Overlapping and Unique Functional and Biochemical Outcomes via Diverse Signaling Pathways , 2004, Molecular and Cellular Biology.

[315]  M. Caligiuri,et al.  Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. , 2009, Blood.

[316]  C. Bokemeyer,et al.  Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.

[317]  C. Sette,et al.  Involvement of Phospholipase Cγ1 in Mouse Egg Activation Induced by a Truncated Form of the C-kit Tyrosine Kinase Present in Spermatozoa , 1998, The Journal of cell biology.

[318]  Johan Lennartsson,et al.  Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit , 2005, Stem cells.

[319]  E. Price,et al.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. , 2000, Genes & development.